Background: The 2-year efficacy and safety of once-weekly (OW) subcutaneous semaglutide
2.4 mg vs placebo in adults with overweight/obesity was assessed in the STEP 5 phase 3 …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Aim To assess health utility values in the Semaglutide Treatment Effect in People with
obesity (STEP) 1‐4 trials. Materials and Methods The STEP 1‐4 phase 3a, 68‐week, double …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Objective This study assessed the effects of semaglutide on body weight, cardiometabolic
risk factors, and glycemic status in individuals categorized by baseline BMI with or without …

Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

Abstract Background A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-
like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …